id	author	title	date	pages	extension	mime	words	sentence	flesch	summary	cache	txt
cord-001566-kkaxha7d	Zhang, Mao-Yu	Development of Monoclonal Antibodies in China: Overview and Prospects	2015-02-25		.txt	text/plain	3525	158	39	The following examples are used to provide a holistic view of mAbs research development in China. Monoclonal antibody therapeutics: history and future Advances in the production and downstream processing of antibodies Continuous cultures of fused cells secreting antibody of predefined specificity Differences in promiscuity for antibody-FcRn interactions across species: implications for therapeutic antibodies Immunogenicity of engineered antibodies Monoclonal antibodies as innovative therapeutics Chimeric human antibody molecules: mouse antigen-binding domains with human constant region domains Reshaping human antibodies: grafting an antilysozyme activity Assembly of combinatorial antibody libraries on phage surfaces: the gene III site A surface expression vector for antibody screening By-passing immunisation: human antibodies from synthetic repertoires of germline VH gene segments rearranged in vitro Production of fully human antibodies by transgenic mice Highavidity human IgG monoclonal antibodies from a novel strain of minilocus transgenic mice Development trends for human monoclonal antibody therapeutics Monoclonal antibody-from murine to humanized The research progress and trend of biotech drugs in reseach years in China Challenges and prospects for monoclonal antibodies in China Early development of antibody therapeutics: key aspects of advancing an antibody drug from research to clinic The development and trend of antibody drugs Rituximab, an anti-CD20 monoclonal antibody: history and mechanism of action Monoclonal antibody therapy of cancer Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance Monoclonal antibodies against human tumor necrosis factor (TNF), and use there of The efficacy and safety of a third anti-TNF monoclonal antibody in Crohn's disease after failure of two other anti-TNF antibodies Failure of treatment with anti-VEGF monoclonal antibody for longstanding POEMS syndrome Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy Efficacy and concentration-response of murine anti-VEGF monoclonal antibody in tumor-bearing mice and extrapolation to humans Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer Antibodies to watch in 2014: mid-year update Molecular mechanisms of resistance to the EGFR monoclonal antibody cetuximab Tumor antigentargeted, monoclonal antibody-based immunotherapy: clinical response, cellular immunity, and immunoescape Monoclonal antibodies-focus point of anti-tumor drugs research Therapeutic effect of infliximab on moderate and severe active rheumatoid arthriti Construction of a single-chain Fv antibody against epidermal growth factor receptor and its antitumor activity Which are the antibodies to watch in 2013 Opportunities and challenges brought by monoclonal antibodies rapid development to biopharmaceutical in China Potent cross-reactive neutralization of SARS coronavirus isolates by human monoclonal antibodies Monoclonal antibody purification with hydroxyapatite Human antibodies for immunotherapy development generated via a human B cell hybridoma technology Current and future issues in the manufacturing and development of monoclonal antibodies New technologies for the generation of human monoclonal antibody Biopharmaceutical industrialization prospect in China based on the antibodies Challenges and opportunities of monoclonal antibody manufacturing in China Development of antibody drugs in China Fully human anti-interleukin-8 monoclonal antibodies: potential therapeutics for the treatment of inflammatory disease states Development of ABX-EGF, a fully human anti-EGF receptor monoclonal antibody, for cancer therapy Biosimilars: challenges and promises cabs workshop on biosimilar therapeutics The integrated simulation and assessment of the impacts of process change in biotherapeutic antibody production Approval of the first biosimilar antibodies in Europe: a major landmark for the biopharmaceutical industry Advances in antibody manufacturing using mammalian cells	cache/cord-001566-kkaxha7d.txt	txt/cord-001566-kkaxha7d.txt
